Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amorfix Life Sciences and the Ontario Genomics have demonstrated that Amorfix's Epitope Protection (EP) technology, is able to detect amyloid, an accumulation of protein aggregates, which are also formed in Alzheimer's disease.
Subscribe to our email newsletter
With this advancement, Amorfix will be committing additional resources to develop an ultra-sensitive blood test for Alzheimer's disease, based upon Amorfix's patent-pending EP technology.
Alzheimer's disease is associated with an accumulation of amyloid in the brain. Recent research has shown that these amyloid aggregates result from aggregation of misfolded abeta protein fragments. Abeta is present in blood and the company believes abeta amyloid aggregates are also present in the circulation in Alzheimer's patients.
“Until now, it has been very difficult to detect aggregated misfolded proteins in blood where the normal protein is abundant. With the knowledge that Epitope Protection works on abeta amyloid aggregates, we are now in a position to finish our development and validate a blood test for Alzheimer's disease,” said Dr Neil Cashman, Amorfix's CSO.
“I am very pleased that OGI's scientific review process has determined we have met this important technical milestone and we will continue to aim to be the first to develop a definitive blood test for Alzheimer's,” said George Adams, Amorfix's CEO.
Pursuant to the subscription agreement, OGI will now invest its second tranche of $50,000 in Amorfix. This transaction is subject to acceptance for filing by the TSX Venture Exchange.